Myelodysplastic syndromes, or MDS, may cause low or abnormal blood cell counts. In MDS, immature stem cells may not mature into healthy, normal blood cells. One newer option that may help is called an erythroid maturation agent, or EMA.
In this video, learn what EMAs are and how they may help treat certain people with MDS, according to Jonathan Feld, MD, Hematology Specialist at The Mount Sinai Hospital in New York City.
Jonathan Feld, MD, is a hematology specialist at The Mount Sinai Hospital.
References
American Cancer Society. (2018). General approach to treatment of myelodysplastic syndromes.
American Society of Hematology. (n.d.). Anemia.
Bristol Myers Squibb. (2020). U.S. Food and Drug Administration (FDA) approves Reblozyl (luspatercept-aamt), the first and only erythroid maturation agent, to treat anemia in adults with lower-risk myelodysplastic syndromes (MDS).
Bristol Myers Squibb. (2022). REBLOZYL [package insert].
Dotson, J. L., et al. (2022). Myelodysplastic syndrome. StatPearls.
Patnaik, M. M., et al. (2021). Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management". American Journal of Hematology.
Why trust our experts?
